Akebia Therapeutics, Inc. (AKBA)
| Market Cap | 408.66M |
| Revenue (ttm) | 225.07M |
| Net Income (ttm) | -15.91M |
| Shares Out | 265.37M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | 78.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,187,573 |
| Open | 1.590 |
| Previous Close | 1.590 |
| Day's Range | 1.530 - 1.600 |
| 52-Week Range | 1.445 - 4.079 |
| Beta | 0.31 |
| Analysts | Strong Buy |
| Price Target | 6.25 (+305.84%) |
| Earnings Date | Nov 10, 2025 |
About AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the t... [Read more]
Financial Performance
In 2024, Akebia Therapeutics's revenue was $160.18 million, a decrease of -17.70% compared to the previous year's $194.62 million. Losses were -$69.41 million, 33.7% more than in 2023.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for AKBA stock is "Strong Buy." The 12-month stock price target is $6.25, which is an increase of 305.84% from the latest price.
News
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...
Akebia Announces Establishment of Rare Kidney Disease Pipeline
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease ind...
Q32 Bio Sells Complement Inhibitor ADX-097
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash ru...
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...
Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript
Akebia Therapeutics, Inc. ( AKBA) Q3 2025 Earnings Call November 10, 2025 8:00 AM EST Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate Communications John Butler - CEO...
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million ; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourt...
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025 Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025
Akebia Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...
Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2025, on ...
FDA Pushback Prompts Akebia To Drop Broad Label Pursuit For Kidney Disease Drug
Akebia Therapeutics Inc. (NASDAQ:AKBA) stock is trading lower on Wednesday.
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDA Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U...
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
Presentations Detail Ongoing Vafseo® (Vadadustat) Real-World Studies and Explore Insights Regarding Clinical Benefits and Dosing of Vafseo Presentations Detail Ongoing Vafseo® (Vadadustat) Real-World ...
Akebia Therapeutics, Inc. (AKBA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Erik Ostrowski - Chief Business Officer, Senior VP, CFO &...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection
I'm bullish on Akebia at $3.13, viewing the 21% post-earnings dip as a buying opportunity ahead of major revenue catalysts. Vafseo's rapid adoption and DaVita's pilot could double Akebia's addressable...
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
CAMBRIDGE, Mass. and FRANKLIN, Tenn.
Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Erik John Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer John P...
Akebia (AKBA) Q2 Revenue Jumps 43%
Akebia (AKBA) Q2 Revenue Jumps 43%
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million ; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to be...
Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to...
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2025, on Thur...
Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to...
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
Akebia continues to publish important, clinically relevant data to further physicians' understanding of Vafseo® (vadadustat) Akebia continues to publish important, clinically relevant data to further ...
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, t...